MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations

作者:Kerstjens Mark; Driessen Emma M C; Willekes Merel; Pinhancos Sandra S; Schneider Pauline; Pieters Rob; Stam Ronald W
来源:Oncotarget, 2017, 8(9): 14835-14846.
DOI:10.18632/oncotarget.11730